- Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
-
Wu KC, Ran ZH, Gao X, Chen M, Zhong J, Sheng JQ, Kamm MA, Travis S, Wallace K, Mostafa NM, Shapiro M, Li Y, Thakkar RB, Robinson A
- KMID: 2425288
- Intest Res.
- 2016 Apr;14(2):152-163.
- doi: 10.5217/ir.2016.14.2.152
BACKGROUND/AIMS: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS: Thirty, adult Chinese patients with CD... -
- CITED
-
- Close
- SHARE
-
- Close
